Benjamin Lane, PhD
For over 16 years, Ben has contributed to the development of pre-clinical through commercial programs at both large and small biotech companies. He joined Nuvalent in October 2020 as the Vice President of Pharmaceutical Development.
Ben started out as a process chemist supporting small molecule development at Biogen, where he helped expand the internal research capabilities and start the first internal kilo-lab. Biogen afforded him the opportunity to quickly become the technical drug substance lead for several Phase 1 and 2 programs in both the neurology and oncology spaces. Following his love for complex synthetic challenges, Ben transitioned to the Process Chemistry group at Infinity Pharmaceuticals to work on the scale up of several semisynthetic natural products, including Saridegib. While serving as the duvelisib drug substance SME, Ben led the process chemistry efforts from drug candidate nomination into process validation. This later resulted in the FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. While at Agios, Ben led the process chemistry group, which was responsible for pre-clinical to commercial drug substance development and manufacturing. Most notably, Ben has been the Technical Operations asset manager for the Mitapivat program for the treatment of hemolytic anemias and has seen the program through from Phase 1 through process validation. Ben earned his degree PhD from Texas A&M University and held a postdoctoral position at Columbia University.